Affiliation:
1. a Department of Internal Medicine, Kufstein County Hospital (Teaching Hospital of Innsbruck Medical University), Kufstein, Austria
2. b Department of Psychiatry and Psychotherapy, Innsbruck Medical University, Innsbruck, Austria
Abstract
Abstract
Learning Objectives
After completing this course, the reader will be able to: Evaluate the effect of various chemotherapy regimens on taste alterations.Investigate the effect of chemotherapy-induced taste alterations on patients and use available dietary approaches such as taste enhancement and substitution of proteins and nutrients of avoided food to improve quality of life.
CME This article is available for continuing medical education credit at CME.TheOncologist.com.
Background.
Taste alterations (TAs) are a frequent but under-recognized treatment side effect in cancer patients undergoing chemotherapy (CT). CT regimens with different toxicity profiles may vary in their impact on TAs, but research on this topic is lacking. This study assesses the prevalence of TAs and their relation to sociodemographic and clinical variables, especially CT regimens. Furthermore, the association between TAs and quality of life (QOL) is investigated.
Patients and Methods.
TAs and QOL data were collected longitudinally in 197 cancer patients (lung cancer, 54.3%; pancreatic cancer, 19.3%; colorectal cancer, 26.4%; age, 65.2 ±10.4 years; male, 57.4%) who were receiving CT at the Department of Internal Medicine at Kufstein County Hospital, giving rise to a total of 1,024 assessment times. Patients completed the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire and two additional questions taken from the EORTC item bank concerning TAs. Statistical analyses were performed using mixed-effect models.
Results.
The study showed that the prevalence of TAs in chemotherapy patients is alarmingly high (69.9%). There were clear differences in TA scores among treatment groups: patients receiving irinotecan reported significantly more TAs than patients in other treatment groups; patients receiving a combination of gemcitabine and a platinum agent reported the lowest TAs. Additionally, significant associations between TAs and several QOL dimensions were found, especially with appetite loss and fatigue.
Conclusion.
The high prevalence of TAs and their impact on QOL in CT patients underscore the urgent need for increased attention to this side effect, both in research and in clinical practice.
Publisher
Oxford University Press (OUP)
Reference31 articles.
1. Perception of chemotherapy side effects cancer versus noncancer patients;Lindley;Cancer Pract,1999
2. Self-reported taste and smell changes during cancer chemotherapy;Bernhardson;Support Care Cancer,2008
3. Drug-induced taste and smell disorders;Henkin;Incidence, mechanisms and management related primarily to treatment of sensory receptor dysfunction. Drug Saf,1994
4. Oral mucosal lesions, microbial changes, and taste disturbances induced by adjuvant chemotherapy in breast cancer patients;Jensen;Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol,2008
5. Abnormalities of taste sensation in cancer patients;DeWys;Cancer,1975
Cited by
162 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献